Terbium-149 production: a focus on yield and quality improvement towards preclinical application.

ABSTRACT: Terbium-149 (T_1/2 = 4.1 h, E_α = 3.98 MeV (16.7%), 28 µm range in tissue) is a radionuclide with potential for targeted alpha therapy. Due to the negligible emission of α-emitting daughter nuclides, toxicity to healthy tissue may be reduced in comparison with other α-particle emitters. In this study, terbium-149 was produced via 1.4 GeV proton irradiation of a tantalum target at the CERN-ISOLDE facility. The spallation products were mass separated and implanted on zinc-coated foils and, later, radiochemically processed. Terbium-149 was separated from the co-produced isobaric radioisotopes and the zinc coating from the implantation foil, using cation-exchange and extraction chromatographic techniques, respectively. At the end of separation, up to 260 MBq terbium-149 wer

SUBMITTER: Favaretto C 

PROVIDER: S-EPMC10853284 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature